Zydus Lifesciences Limited — Letrozole Exporter Profile
Indian Pharmaceutical Exporter · #5 for Letrozole · $739.2K export value · DGFT Verified
Zydus Lifesciences Limited is the #5 Indian exporter of Letrozole with $739.2K in export value and 35 verified shipments. Zydus Lifesciences Limited holds a 2.3% market share in Letrozole exports across 7 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
Zydus Lifesciences Limited — Letrozole Export Profile: Buyers & Destinations
Where Does Zydus Lifesciences Limited Export Letrozole?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SRI LANKA | $283.1K | 11 | 49.6% |
| THAILAND | $196.6K | 5 | 34.4% |
| SPAIN | $36.6K | 3 | 6.4% |
| GUYANA | $18.0K | 1 | 3.1% |
| FRANCE | $14.6K | 2 | 2.6% |
| BRAZIL | $11.0K | 1 | 1.9% |
| PHILIPPINES | $10.9K | 12 | 1.9% |
Zydus Lifesciences Limited exports Letrozole to 7 countries. The largest destination is SRI LANKA accounting for 49.6% of Zydus Lifesciences Limited's Letrozole shipments, followed by THAILAND (34.4%) and SPAIN (6.4%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Letrozole from Zydus Lifesciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| HEMAS PHARMACEUTICALS (PVT) LTD | SRI LANKA | $233.1K | 10 |
| PHARMALAND (1982) CO. LTD | THAILAND | $196.6K | 5 |
| HEMAS PHARMACEUTICALS (PRIVATE) LIMITED | SRI LANKA | $50.0K | 1 |
| LABORATORIOS COMBIX SLU | SPAIN | $23.6K | 2 |
| NEW GPC INC | GUYANA | $18.0K | 1 |
| DHL GLOBAL FORWARDING (SPAIN) | SPAIN | $13.0K | 1 |
| ZYDUS NIKKHO FARMACEUTICA LTDA | BRAZIL | $11.0K | 1 |
| ZYDUS HEALTHCARE PHILIPPINES INC. | PHILIPPINES | $9.7K | 10 |
| CENTRE SP?CIALIT?S PHARMACEUTIQUES | FRANCE | $7.3K | 1 |
| CENTRE SPECIALITES PHARMACEUTIQUES | FRANCE | $7.3K | 1 |
Zydus Lifesciences Limited supplies Letrozole to 11 buyers globally. The largest buyer is HEMAS PHARMACEUTICALS (PVT) LTD (SRI LANKA), followed by PHARMALAND (1982) CO. LTD (THAILAND) and HEMAS PHARMACEUTICALS (PRIVATE) LIMITED (SRI LANKA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Letrozole Export Value and How Much Does Zydus Lifesciences Limited Contribute?
India exported $18.6M worth of Letrozole through 2,112 shipments from 252 suppliers to 117 countries, serving 508 buyers globally. Zydus Lifesciences Limited contributes $739.2K to this total, accounting for 2.3% of India's Letrozole exports. Zydus Lifesciences Limited ships Letrozole to 7 countries through 11 buyers.
What Is the Average Shipment Value for Zydus Lifesciences Limited's Letrozole Exports?
Zydus Lifesciences Limited's average Letrozole shipment value is $21.1K per consignment, based on 35 shipments totaling $739.2K. The largest destination is SRI LANKA (49.6% of Zydus Lifesciences Limited's Letrozole exports).
How Does Zydus Lifesciences Limited Compare to Other Indian Letrozole Exporters?
Zydus Lifesciences Limited ranks #5 among 252 Indian Letrozole exporters with a 2.3% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($6.9M), CIPLA LIMITED ($4.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($2.4M). Zydus Lifesciences Limited processed 35 shipments to 7 destination countries.
What Letrozole Formulations Does Zydus Lifesciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| LETOV 2.5 (LETROZOLE) 3 X 10 T B.No M210 | $100.0K | 2 |
| LETOV 2.5MG TABS (LETROZOLE) 10 X 10 T U | $91.2K | 5 |
| LETOV 2.5 (LETROZOLE) 3X10 T | $89.3K | 2 |
| LETOV 2.5 TABLETS (LETROZOLE 2.5MG) 3X10T UNDER LUT NO.AD240323012473N DATED 14.03.2023 VALID UP TO 31.03.2024. | $68.7K | 2 |
| LETOV 2.5 TABLETS (LETROZOLE 2.5MG) 3X10 T UNDER LUT NO. AD240324091585Z DATED19.03.2024 VALID UP TO 31.03.2025. | $50.0K | 1 |
| LETOV 2.5 Tablets 3x10 T(LETROZOLE 2.5MG)(3X10 T) | $50.0K | 1 |
| LETOV 2.5 Tablets (LETROZOLE TABS USP 2.5MG) 3X10 T SHIPMENT UNDER LUT No.AD240324091585Z Dated 19.03.2024 valid up to 3 | $20.6K | 1 |
| ONCOLET 2.5 MG TAB 10X10 TAB SALE DOM (LETROZOLE TABLETS IP 2.5 MG)(10X10T) | $18.0K | 1 |
| PHARMA PRODUCT:LETROZOLE TAB 2.5 MG 30'S | $14.6K | 2 |
| PHARMA MEDICINE FOR HUMAN USE-LETROZOL 2.5 MG COMBIX TABLETS (LETROZOLE) 3 X 10T-QTY-11,172.000 PAC-AS PER INV | $14.1K | 1 |
Zydus Lifesciences Limited exports 26 distinct Letrozole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LETOV 2.5 (LETROZOLE) 3 X 10 T B.No M210 with 2 shipments worth $100.0K.
How Does Zydus Lifesciences Limited Compare to Nearest Letrozole Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $2.4M | 56 | 8 | $43.3K |
| 4 | EUGIA PHARMA SPECIALITIES LIMITED | $1.8M | 119 | 9 | $15.3K |
| 5 | ZYDUS LIFESCIENCES LIMITED ★ | $739.2K | 35 | 7 | $21.1K |
| 6 | NAPROD LIFE SCIENCES PRIVATE LIMITED | $581.6K | 12 | 2 | $48.5K |
| 7 | NATCO PHARMA LIMITED | $512.8K | 29 | 6 | $17.7K |
Zydus Lifesciences Limited ranks #5 among 252 Indian Letrozole exporters. Average shipment value of $21.1K compared to the market average of $74.0K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
Which Indian Ports Ship Letrozole Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 404 | 19.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 393 | 18.6% |
| MUNDRA SEA (INMUN1) | 109 | 5.2% |
| AHEMDABAD AIR ACC (INAMD4) | 107 | 5.1% |
| MUNDRA SEA | 102 | 4.8% |
| DELHI AIR CARGO ACC (INDEL4) | 100 | 4.7% |
| Bombay Air | 99 | 4.7% |
| HYDERABAD AIR | 89 | 4.2% |
Geopolitical & Trade Policy Impact on Zydus Lifesciences Limited's Letrozole Exports
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Zydus Lifesciences Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Letrozole, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Letrozole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Letrozole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Zydus Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 35 individual customs records matching Zydus Lifesciences Limited exporting Letrozole, covering 26 formulations to 7 countries via 11 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 117+ countries, 508+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Letrozole Export Data from Zydus Lifesciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Letrozole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
Letrozole Stats
Company Overview
Top Products by Zydus Lifesciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Letrozole. For current shipment-level data, contact TransData Nexus.